论文部分内容阅读
目的:观察罗格列酮联合胰岛素治疗2型糖尿病的疗效。方法:112例2型糖尿病患者分成对照组56例(继续应用胰岛素)、治疗组56例(在应用原剂量胰岛素基础上加用罗格列酮,4mg/d,共用3个月)。观察治疗前后空腹血糖(EPG)、餐后血糖(PPC)、糖化血红蛋血(HbAlc)、空腹胰岛素(FINS)、血甘油三酯)(TG)、体重指数(BMI)。结果:治疗组治疗后FPG、PPG、HbAlc、TG均有明显下降,对照组治疗前后上述指标均无明显改变(P<0.05)。结论:胰岛素增敏剂罗格列酮能安全、有效地改善血糖水平,提高胰岛素敏感性,降低胰岛素抵抗,改善胰岛细胞功能。
Objective: To observe the effect of rosiglitazone combined with insulin on type 2 diabetes mellitus. Methods: One hundred and twelve patients with type 2 diabetes were divided into control group (56 cases) and control group (56 cases). 56 cases were treated with rosiglitazone (4mg / d on the basis of the original dose of insulin) for 3 months. The levels of fasting blood glucose (EPG), postprandial blood glucose (PPC), glycosylated hemoglobin (HbAlc), fasting insulin (FINS), triglyceride (TG) and body mass index (BMI) were observed before and after treatment. Results: The levels of FPG, PPG, HbAlc and TG in the treatment group decreased significantly after treatment, but there was no significant change in the control group before and after treatment (P <0.05). Conclusion: Rosiglitazone, an insulin sensitizer, can improve blood sugar level safely and effectively, improve insulin sensitivity, reduce insulin resistance and improve islet cell function.